According to the deal, Gilead will pay GlobeImmune an upfront payment and provide support for continued development of GlobeImmune’s HBV therapeutic vaccine programme through Phase 1a clinical trials.
The antibody is a dye conjugate which will be used in Phase I and Phase II clinical trials. Spectros CEO David Benaron said the collaboration with GBI on
Sativex has been developed by the UK-based GW Pharmaceuticals and is marketed in Europe (except the UK) by Almirall. The Phase III studies demonstrated the long term efficacy
Under the terms of thecollaboration, Mirna will provide Silence with specific miRNA sequences, to formulate with AtuPLEX and DBTC delivery systems and develop multiple candidate drugs. Mirna, on
Lead researcher Professor Nakajima discovered the Rheumatoid Arthritis (RA) biomarker and therapeutic target Synoviolin/Hrd1, a ubiquitin E3 ligase overexpressed in RA patients. As per the terms of the
Linaclotide, an investigational drug, is an agonist of the guanylate cyclase type-C (GC-C) receptor located on the luminal surface of the intestine. The NDA for linaclotide was submitted
The facility will now include reactor vessels with clean room product isolation and drying equipment to allow Highly Potent API manufacture up to 600kg batch size. The expansion,
Immunologix has developed mAbLogix platform, which enables the ability to derive fully human antibodies. The antibodies target all antigen types including, cancer cells, viruses, bacteria, toxins, as well
The entire transaction will amount to $415m. As per the deal, Cubist will purchase all of the outstanding shares of Adolor for the upfront cash payment and a
Dulera Inhalation Aerosol, which is used to treat asthma combines mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist. The two 26-week, multicenter, double-blind, placebo controlled
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.